The shares of Pfizer Inc., one of the world's largest pharmaceutical companies, continue to correct, trading above 45.00.
The pressure on the quotes intensifies after the news of the Moderna Inc. lawsuit against the joint venture Pfizer Inc. and BioNTech SE due to a possible patent infringement on the first COVID-19 vaccine: it is accused of copying technology that Moderna Inc. developed a year before the pandemic. This claim does not require specific monetary compensation, and if successful, the amount of compensation can be calculated based on lost profits, which will be the difference in the proceeds from the sale of vaccines. Thus, Moderna Inc. earned 10.4B dollars from its vaccine, while Pfizer Inc. amounted to 22.0B dollars.
The financial report for the second quarter showed revenue of 27.74B dollars, which surpassed both the 25.49B dollars forecast by analysts and 25.66B dollars the previous quarter. EPS came in at 2.04 dollars, higher than analysts' expectations of 1.72 dollars and well above 1.62 dollars in the first quarter.
The next dividend payment is scheduled for September 9, when investors will receive 0.4 dollars per share, and the dividend yield may reach 3.08% per annum.
The trading instrument is moving in the global corrective trend, trying to get out of the Triangle pattern. Technical indicators hold a sell signal: fast EMAs of the Alligator indicator are well below the signal line, and the AO oscillator histogram forms downward bars below the transition level.
Resistance levels: 46.80, 51.00. | Support levels: 45.40, 41.30.